Rilpivirine for pediatric HIV-1 patients weighing 14–25 kg has received FDA approval.

Published Date: 24 Mar 2024

The indicated population may be administered the HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) using 25 mg oral tablets or the new 22.5 mg oral tablets, which were designed to facilitate administration and weight-adjusted dosing for children.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot